Rapamycin Improves the Response of Effector and Memory CD8(+) T Cells Induced by Immunization With ASP2 of Trypanosoma cruzi

Barbara Ferri Moraschi
Federal University of São Paulo (UNIFESP)

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Immunopathology Commons, Parasitic Diseases Commons, Parasitology Commons, and the Pathogenic Microbiology Commons

Repository Citation

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMMS Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Rapamycin Improves the Response of Effector and Memory CD8+ T Cells Induced by Immunization With ASP2 of Trypanosoma cruzi

Barbara Ferri Moraschi1,2, Isaú Henrique Noronha1,2, Camila Pontes Ferreira1,2, Leonardo M. Cariste3, Caroline B. Monteiro3, Priscila Denapoli1, Talita Vrechi4, Gustavo J. S. Pereira4, Ricardo T. Gazzinelli5,6, Joseli Lannes-Vieira7, Mauricio M. Rodrigues1,2†, Karina R. Bortoluci1,4 and José Ronnie C. Vasconcelos1,2,3*

1 Molecular Immunology Laboratory, Center of Molecular and Cellular Therapy, Federal University of São Paulo (UNIFESP), São Paulo, Brazil, 2 Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil, 3 Recombinant Vaccines Laboratory, Department of Biosciences, Federal University of São Paulo, Santos, Brazil, 4 Department of Pharmacology, Federal University of São Paulo, (UNIFESP), São Paulo, Brazil, 5 René Rachou Research Center, Fiocruz, Belo Horizonte, Brazil, 6 Division of Infectious Disease and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States, 7 Laboratory of Biology of the Interactions, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil

Deficiency in memory formation and increased immunosenescence are pivotal features of Trypanosoma cruzi infection proposed to play a role in parasite persistence and disease development. The vaccination protocol that consists in a prime with plasmid DNA followed by the boost with a deficient recombinant human adenovirus type 5, both carrying the ASP2 gene of T. cruzi, is a powerful strategy to elicit effector memory CD8+ T-cells against this parasite. In virus infections, the inhibition of mTOR, a kinase involved in several biological processes, improves the response of memory CD8+ T-cells. Therefore, our aim was to assess the role of rapamycin, the pharmacological inhibitor of mTOR, in CD8+ T response against T. cruzi induced by heterologous prime-boost vaccine. For this purpose, C57BL/6 or A/Sn mice were immunized and daily treated with rapamycin for 34 days. CD8+ T-cells response was evaluated by immunophenotyping, intracellular staining, ELISpot assay and in vivo cytotoxicity. In comparison with vehicle-injection, rapamycin administration during immunization enhanced the frequency of ASP2-specific CD8+ T-cells and the percentage of the polyfunctional population, which degranulated (CD107a+) and secreted both interferon gamma (IFNγ) and tumor necrosis factor (TNF). The beneficial effects were long-lasting and could be detected 95 days after priming. Moreover, the effects were detected in mice immunized with ten-fold lower doses of plasmid/adenovirus. Additionally, the highly susceptible to T. cruzi infection A/Sn mice, when immunized with low vaccine doses, treated with rapamycin, and challenged with trypomastigote forms of the Y strain showed a survival rate of 100%, compared with 42% in vehicle-injected group. Trying to shed light on the biological mechanisms involved in these beneficial effects on CD8+ T-cells by mTOR inhibition after immunization, we showed that in vivo proliferation was higher after rapamycin treatment compared with vehicle-injected group. Taken
INTRODUCTION

The immunization regimen known as heterologous prime-boost vaccination uses two distinct vectors for priming and boosting, both carrying the target antigen. Different combinations of vectors have been tested and the application of this strategy has promoted an immune response against several experimental infections, such as simian immunodeficiency virus (SIV), malaria, Ebola, tuberculosis, Chagas disease, toxoplasmosis and COVID-19 (Li et al., 1993; McConkey et al., 2003; Wilson et al., 2006; Zhang et al., 2007; De Alencar et al., 2009; Elvang et al., 2009; Hensley et al., 2010; Hill et al., 2010; Martins et al., 2010; Chuang et al., 2013; Graham et al., 2020). This regimen began to be studied more than 20 years ago and has shown excellent protective responses both to intracellular pathogens and neoplastic cells due to the induction of cytotoxic CD8+ T-cells (Zavala et al., 2001; Gilbert et al., 2002; Ranasinghe and Ramshaw, 2009).

Chagas disease, caused by the intracellular protozoan Trypanosoma cruzi, is an endemic disease in Latin America and considered a neglected one by the World Health Organization (WHO), as it affects approximately 6-7 million people worldwide (World Health Organization, 2016). The clinical course of Chagas disease generally comprises acute and chronic phases and affects mainly the heart and the digestive system. Currently, the treatment consists of administering the chemotherapeutic benznidazole or nifurtimox, but these drugs have limited efficacy when started late, and there are still no vaccines for the disease (Pérez-Molina and Molina, 2017).

The heterologous prime-boost vaccination protocol, capable of conferring a significant degree of protection against experimental T. cruzi infection, consists of priming immunization with plasmid DNA, followed by boosting with replication-defective human recombinant adenovirus type 5, both vectors expressing the amastigote surface protein-2 (ASP2) (De Alencar et al., 2009; Haolla et al., 2009; Dominguez et al., 2011; Rigato et al., 2011; Vasconcelos et al., 2012; Ferreira et al., 2017). Previously, we demonstrated that this prime-boost protocol generates a high frequency of effector CD8+ T cells (CD44High, CD11aHigh, CD62LLow, CD127Low and KLRG1High), which subsequently acquire an effector memory phenotype (CD44High, CD11aHigh, CD62LLow, CD127+ and KLRG1High) (Rigato et al., 2011). These phenotype and cytotoxic effector activity were long-lasting, being detected 98 days after boosting (De Alencar et al., 2009; Rigato et al., 2011). Moreover, the effector memory CD8+ T-cells (TEM) induced by heterologous prime-boost immunization are polyfunctional, since express IFNγ, TNF and CD107a, and play cytotoxic activity simultaneously (De Alencar et al., 2009; Rigato et al., 2011).

During the specific immune response development, several signaling pathways are required to activate T-cells and initiate their differentiation. The highly conserved kinase called mammalian target of rapamycin (mTOR) is a key regulator of essential cellular processes such as cell growth, autophagy, survival, proliferation, and metabolism in response to environmental factors, including levels of cellular energy, insulin, cytokines and amino acids, through the complexes mTORC1 and mTORC2, that contain different scaffold associated proteins, Raptor and Rictor, respectively, which define their downstream targets pathways (Dennis et al., 2001; Wullschleger et al., 2006; Thomson et al., 2009; Powell et al., 2012). In CD8+ T-cells, mTORC1 controls, for example, glucose uptake and glycolysis during activation and effector phases and also participates in the signaling generated by the antigen recognition receptor (TCR) and cytokines (Jacobs et al., 2008; Buck et al., 2015; Chang and Pearce, 2016). Even though rapamycin has been commonly used in organ transplantation to prevent graft rejection (Augustine et al., 2007), several studies have reported that mTOR inhibition by treatment with low and continuous doses of rapamycin during the immune challenge of CD8+ T cells could improve the function and memory formation following viral infections or tumor challenges (Araki et al., 2009; Rao et al., 2010; Li et al., 2011; Turner et al., 2011; Bassett et al., 2012; Mattson et al., 2014; Shrestha et al., 2014).

The transcriptome of activated CD8+ T cells treated with rapamycin revealed that most genes modulated by mTOR inhibitor are associated with apoptosis, survival, maintenance, and cell migration, which take part in the CD8+ T cell programming and their downstream targets pathways (Dennis et al., 2001; Wullschleger et al., 2006; Thomson et al., 2009; Powell et al., 2012). Based on these findings, here we tested the role of the mTOR inhibitor rapamycin combined with heterologous prime-boost immunization against T. cruzi during CD8+ T-cell activation. For this purpose, C57BL/6 and AS/n mice were immunized and daily treated with rapamycin. The inflammatory and cytolytic immune responses were analyzed. Additionally, mice were challenged with the highly infective trypomastigote forms of Y strain.

METHODS

Ethics Statement

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of
Laboratory mice of the Brazilian National Council of Animal Experimentation (http://www.sbcl.org.br/) and Federal Law 11.794 (October 8, 2008). The project was approved by the Ethical Committee for Animal Experimentation at the Federal University of Sao Paulo, registered under number 9959021014.

Mice and Parasites
Male and female 8-week-old C57BL/6 and A/Sn mice were supplied by the Center for the Development of Experimental Models for Medicine and Biology (CEDEME) from the Federal University of São Paulo. Blood trypomastigotes of Y type II strain of T. cruzi were maintained by weekly passages in A/Sn mice at the Xenodiagnostic Laboratory of Dante Pazzanese Institute of Cardiology. For in vivo experiments, the challenge was performed with 150 or 1 x 10⁴ trypomastigotes diluted in PBS (0.2 mL) in A/Sn and C57BL/6 mice, respectively, administered subcutaneously (s.c.) in the tail. Parasitemia was monitored after the 6th day of infection until day 15. A blood sample (5 µl) was collected from the tail for parasite quantification on the light microscope.

Immunization Protocol
The heterologous prime-boost immunization protocol previously described by Rigato and group (Rigato et al., 2011) was used in this study. The protocol consists of a dose of plasmid DNA, with the vectors pcDNA3 (control) or plgSPClone9, at 10 or 100 µg/mouse. Three weeks after the first immunization, mice were immunized with 2 x 10⁶ or 2 x 10⁶ pfu of the adenoviral vectors Adβ-Gal (control) or AdASP-2. Both immunizations were performed by intramuscular route in the Tibialis anterior muscle. Experimental groups were delineated as follows: 1) Control: immunized with the control vectors pcDNA3 and Adβ-Gal; 2) ASP2: immunized with plgSPCL9/AdASP-2 and vehicle-injected (PBS); 3) ASP2/rapamycin: immunized with plgSPCL9/AdASP-2 and rapamycin-treated.

Treatment With Rapamycin
Mice were treated every 24 hours with 2 µg rapamycin (Sigma Aldrich) per mouse (0.075 mg/kg/day), diluted in 0.2 mL PBS intraperitoneal (i.p.) for 34 days, starting at priming (Li et al., 2011; Bassett et al., 2012). Control mice were treated with the vehicle (PBS). To assess mTOR inhibition, phospho-S6 ribosomal protein conjugate antibody (Ser235/236) from Cell Signaling Technology was used. This antibody binds to the PS6 ribosomal protein only in its phosphorylated form, indicating whether mTOR was activated. For phospho-S6 ribosomal protein staining, the protocol was performed according to Ersching and group (Ersching et al., 2017).

Peptides and Multimers
The ASP2 synthetic peptides VNHRFTLV and TEWETGQI were synthesized by GenScript with purity greater than 95%. The peptides were used during in vivo and ex vivo assays to stimulate specific CD8⁺ T-cells.

H₂Kᵇ⁻VNHRFTLV multimer was purchased from ProImmune Inc., and H₂Kᵇ⁻TEWETGQI multimer, labeled with allophycocyanin, was purchased from Immudex. Both were used for labeling TCR-specific CD8⁺ T-cells.

Flow Cytometry Analysis
Splenocytes were treated with ACK buffer (NH₄Cl, 0.15 M, KHCO₃, 10 mM, 0.1 mM Na₂-EDTA, pH 7.4) for osmotic lysis of red cells and washed with RPMI supplemented with 10% fetal bovine serum (FBS). After lysis, cells were labeled with the multimers for 10 minutes at room temperature. The cell surface was stained for 30 min at 4°C with the following antibodies: anti-CD8 (clone 53-67), anti-CD11a (clone 2D7), anti-CD11c (clone HL3), anti-CD25 (clone 7D4), anti-CD27 (clone LG.7F9), anti-CD31 (clone MEC13.3), anti-CD43 (clone Ly 48), anti-CD43 (clone 1B1), anti-CD44 (clone IM7), anti-CD49d (clone R-12), anti-CD62L (clone MEL-CD70 (clone FR70), anti-CD95 (clone Jo2), anti-CD95L (MFL3), anti-CD122 (clone TM-b1), anti-CD127 (clone J43), anti-PDL-1 (clone MIH5), anti-CCR-5 (clone HM-CCR5), anti-CCR-7 (clone 4B12), anti-KLRG-1 (clone 2F1 and anti-CD183 (CXCR3-clonel). At least 500,000 events were acquired on FACS Canto II flow cytometer (BD). The results were analyzed with FlowJo software version 9.9.6 (FlowJo, LLC).

Intracellular Cytokine Staining
Two million splenocytes were incubated in the presence or absence of the peptides VNHRFTLV or TEWETGQI (10 µg/mL or 10 µM) in supplemented RPMI medium with CD107a FITC antibody (clone 1D4B, BD), anti-CD28 (clone 37.51, BD Bioscience), BD Golgi-Plug (1 µL/mL, BD Bioscience) and monensin (5 µg/mL, Sigma Aldrich) no longer than 12 hours in V-bottom 96-well plates (Corning) in a final volume of 200 µL, at 37°C containing 5% CO₂. After incubation, cells were labeled with anti-CD8 antibody PerCP (clone 53-6.7, BD) for 30 minutes at 4°C. For cellular fixation and permeabilization, the Cytofix/ Cytoperm kit (BD Biosciences) was used according to the supplier’s instructions. For intracellular staining, was used the following antibodies: anti-IFNγ APC (clone XMG1.2, BD Biosciences) and anti-TNF PE (clone MIPC-XT22, BD Biosciences). At least 700,000 events were acquired using a FACSCanto II flow cytometer (BD Biosciences).

Enzyme-Linked-ImmunoSpot Assay (ELISpot)
The IFNγ secretion was measured by ELISpot as described previously (Ferreira et al., 2017). Briefly, 10⁵ responder cells (represented by splenocytes from mice previously immunized) were incubated with 3 x 10⁵ antigen-presenting cells (represented by splenocytes from naïve mice) on nitrocellulose 96-wells flat-bottom plates (Millipore) in the presence or absence of the specific ASP2 peptides VNHRFTLV or TEWETGQI for CD8⁺ T cells for 24 hours. The number of IFNγ-producing cells was determined using a stereoscope. The final value refers to the numeric average of spots of stimulated wells minus the numeric average of spots of unstimulated wells. The result is multiplied by 10 to display the data by spot forming cells (SFC) in million units.
Cytokine Determination
One million splenocytes were incubated for 48 hours in the presence or absence of the peptide VNHRFTLV in a final concentration of 10 μg/mL. Culture supernatants were harvested and stored at −80°C until analysis. IL-2, IL-4, IL-6, IL-10, IL-17, IFNγ, and TNF cytokines were detected simultaneously using mouse Th1/Th2/Th17 cytokine bead array (CBA) kit (BD Pharmingen), according to the manufacturer’s instructions. After acquiring samples on a flow cytometer, the data were analyzed in FCAP Array™ software to generate results in graphical and tabular format. The data are expressed in pg/mL and the values correspond to the number of the value of stimulated samples minus the value of unstimulated ones.

In Vivo Cytotoxicity Assay
Splenocytes from naïve mice were divided into two populations stained with carboxyfluorescein succinimidyl ester (CFSE - Molecular Probes) at a final concentration of 10 μM (CFSEHigh) and 1 μM (CFSELow). PKH26 Red Fluorescent Cell Linker (Sigma-Aldrich) was also used at a final concentration of 20 μM. The target cells labeled with CFSEHigh or PKH were pulsed with peptide VNHRFTLV or TEWETGQI for 40 minutes at 37°C according to each experiment’s concentration. CFSELow cells remained uncoated. Subsequently, all stained populations were counted and mixed at the same proportion. 4 x 10^7 cells were transferred via intravenous into mice and after 14 hours, the spleens of recipient mice were collected to CFSELownaive, CFSEHigh and PKH detection by flow cytometry using FACS Canto II. The percentage of specific lysis was determined by this formula:

\[
\%\text{Lysis} = 1 - \frac{\text{CFSEHigh immunized} \times \text{CFSELow naive}}{\text{CFSEHigh naive} \times \text{CFSELow naive}} \times 100
\]

BrdU Proliferation Assay
For in vivo proliferation, A/Sn mice were treated with 2 mg of BrdU (SIGMA) (i.p.) after boosting for 14 days every 48 hours. Then, the splenocytes were purified with staining with anti-CD8 and BrdU detection according to the manufacturer’s instructions (BrdU Flow Kit APC or FITC - BD Pharmingen). At least 100,000 cells were obtained in low flow rate on a BD FACSCanto II flow cytometer (BD Bioscience), and then analyzed with FlowJo software (FlowJo, LLC).

BMDC Generation, Immunophenotyping Antigen-Presentation Capacity
Bone marrow dendritic cells (BMDC) were generated as described earlier (Ersching et al., 2016). Overall, cells removed from the femurs were cultured with 20 ng/ml of recombinant granulocyte–macrophage colony-stimulating factor (rGM-CSF-RD System) for 7 days. The medium was replaced on the fourth day. In some conditions, BMDC were matured with 200 ng/ml of LPS from E. coli (Sigma-Aldrich) for 3 hours, resulting in a population that comprises around 80% of CD11c+ cells. For in vitro antigen presentation capacity assay, BMDC were incubated with AdASP-2 (MOI = 50) for 24 hours, or with VNHRFTLV peptide (10 μg/mL) for 1 hour. Rapamycin was used in a final concentration of 1 μM. The frequency of IFNγ-producing by CD8+ T cells was detected by ELISpot. Additionally, BMDC were stained with the following antibodies for flow cytometry analysis: anti-CD11c, anti-CD40, anti-CD86 and anti-MHC class I (H2Kb).

Statistical Analysis
Groups were compared using One-way ANOVA followed by Tukey’s HSD test on Vassarstats (http://vassarstats.net). Before performing parametric tests, the normal distribution was analyzed by Shapiro-Wilk test and residuals distribution in QQ-plots on GraphPad Prism 8.0. Survival analysis by Log-rank was also performed on GraphPad Prism 8.0. Because the variances were similar, values were expressed as mean ± standard deviations (SD). The expression of the receptors was compared by MFI (mean fluorescence intensity), and the MFI of naïve group was taken as a baseline. Differences were considered significant when the p value was <0.05.

RESULTS
Rapamycin Treatment Enhances the Number and Quality of Specific CD8+ T-Cells
Initially, the blockade of mTOR by rapamycin was confirmed by ribosomal protein S6 staining, which is a target of mTOR kinase. The detection antibody used binds to S6 ribosomal protein only in its phosphorylated form (Ser235/236), indicating whether there was mTOR activity. CD8+ T cells from splenocytes of C57BL/6 mice incubated with rapamycin for 1 hour showed a lower expression of phosphorylated S6K than untreated or concavalin A stimulated cells (Supplementary Figure 1).

T lymphocytes perform a strong antiparasitic role mediated by the secretion of IFNγ and other mediators that also participate in the parasite dissemination control. The CD8+ T-cells induced by heterologous prime-boost regimen are polyfunctional, as they exhibit cytotoxic activity and secrete the cytokines IFNγ and TNF simultaneously (De Alencar et al., 2009; Rigato et al., 2011). Based on these findings, we evaluated the production of cytokines IFNγ and TNF, as well as the degranulation by the expression of the CD107a molecule (LAMP-1) in VNHRFTLV peptide-specific CD8+ T-cells obtained from splenocytes of immunized mice. Experimental groups were delineated as follows: 1) Control: immunized with the control vectors pcDNA3 and Adβ-Gal; 2) ASP2: immunized with pIgSPCl.9/AdASP-2 and vehicle-injected (PBS); 3) ASP2/rapamycin: immunized with plgSPCL9/AdASP-2 and rapamycin-treated.

After ex vivo stimulation with the peptide VNHRFTLV and intracellular staining (gates strategy showed in Supplementary Figure 2), the number of CD8+ T-cells that simultaneously express IFNγ, TNF and CD107a, named polyfunctional subpopulation, were increased in rapamycin-treated mice (Gr.3), compared with vehicle-injected mice (Gr.2), after Boolean analysis (Figures 1B, C). In addition, the magnitude of responding CD8+ T-cells (frequency of cells that express at least one of the three molecules IFNγ or TNF or CD107a after ex
vivo stimulus with the specific peptide) was also higher in Gr.3 (Figure 1A), at 35 days after priming. The differences between Gr.2 (vehicle-injected) and Gr.3 (rapamycin-treated) were more evident at 95 days after priming (Figures 1D–F).

In order to measure the frequency of ASP2 specific CD8+ T-cells, the splenocytes were labeled with the H2Kb-VNHRFTLV pentamer and anti-CD8. We found that the frequency and absolute number of specific CD8+ T-cells were significantly higher in Gr.3 after 35 days and sustained after 95 days after priming (Figures 2A–C). These results demonstrate that treatment with rapamycin enhances the response generated by immunization and memory formation, confirming that inhibition of mTOR modulates T-lymphocyte differentiation during adaptive immunity to T. cruzi antigens, as previously proposed in other conditions (Araki et al., 2009; Nam, 2009).

**Specific CD8+ T-Cells Phenotype Remains Unchanged After Treatment With Rapamycin**

Traditionally, antigen-specific CD8+ T-cells are divided into three major groups according to their markers of activation, homing, migration, proliferation capacity and effector functions: i) effectors (TE): effector cells that control the infection (CD44High, CD11aHigh, CD62LLow, CD127-, KLRG1High); ii) central memory (TCM): long-lasting memory cells with high proliferative potential after antigen stimulation and reside in secondary lymphoid organs (CD44High, CD11aHigh, CD62LHigh, CD127+, KLRG1High); iii) effector memory (TEM): transitional cells that exist for a shorter time, present high effector activity and express TE surface markers (CD44High, CD11aHigh, CD62LLow, KLRG1High) and a TCM marker (CD127+). They home primarily in peripheral tissues and rapidly produce effector cytokines upon antigenic stimulation (Wherry et al., 2003; Lanzavecchia and Sallusto, 2005; Wirth et al., 2009; Wirth et al., 2010; Angelosanto and Wherry, 2010; Cui and Kaech, 2010; Ahmed and Akondy, 2011; Sheridan and Lefranc̆ois, 2011).

Previously, it has been shown that heterologous prime-boost regimen induces a strong response of effector CD8+ T-cells, which develop into an effector memory (TEM) population (Rigato et al., 2011). Here, we challenged the hypothesis that mTOR inhibition changes the profile of CD8+ T-cells generated by vaccination as, for example, into a TCM phenotype, as described in other experimental models combined with rapamycin (Araki et al., 2009; Pearce et al., 2009; Turner et al., 2011). To this end, we performed the phenotypic characterization of specific CD8+ T-cells from the spleen of C57BL/6 mice immunized and treated with rapamycin or vehicle.

Specific CD8+ T-cells were stained with H2Kb-VNHRFTLV multimer and anti-CD8. The expression pattern of the molecules CD11a, CD44, CD62L, CD127, KLRG-1 and CCR7 on specific CD8+ T-cells was similar between Gr.2 and Gr.3, at 35 and 95 days after priming (Figure 2D), showing that rapamycin, all in all, did not modify the TE(M) profile of CD8+ T-cells generated by
vaccination. In both ASP2 immunized groups, differently from the expected, an increase in CD127 expression on specific CD8+ T cells was not found after 95 days. Other markers involved with activation and migration were not altered either. The complete immunophenotyping, where twenty-four surface markers associated with activation, regulation, migration, and cell death were used, is shown in Supplementary Figures 3 and 4.

**Cellular Response Remained High Even With Reduced Doses of Immunization in Rapamycin-Treated C57BL/6 Mice**

Next, we evaluated the role of rapamycin during vaccination with reduced doses, to highlight the adjuvant effect of rapamycin. For that purpose, C57BL/6 mice were vaccinated with 10-fold lower doses of plasmid/adenovirus, treated with rapamycin or vehicle and the immune response was assessed by the standard protocol. On days 35 and 95, splenocytes were isolated and stained with H2Kb-restricted VNHRFTLV multimer. Splenocytes were stimulated with VNHRFTLV specific ASP-2 peptide for ELISpot anti-IFNγ. The increase in the number of VNHRFTLV-specific CD8+ T cells was replicated with 10-fold lower doses since the rapamycin-treated mice showed a higher frequency of specific CD8+ T cells (Gr.3L), both on days 35 and 95 after priming (Figures 3A, B). Later, when we analyzed the IFNγ secretion by CD8+ T-cells after ex vivo stimulation with the VNHRFTLV peptide, rapamycin-treated group (Gr.3L) was superior in both analyses (Figures 3C-E).

In addition, we determined the concentration of cytokines in the supernatant of VNHRFTLV-stimulated splenocytes from mice immunized 95 days after priming using Th1/Th2/Th17
CBA kit. IFNγ was the predominant cytokine after VNHRFTLV stimulation and the splenocytes from rapamycin-treated mice (Gr.3L) presented the highest IFNγ concentration in the supernatants (Figure 3F). As previously shown, heterologous prime-boost vaccination induces predominantly a Th1 profile response (De Alencar et al., 2009). Thus, the present findings enable us to adopt a protocol with reduced doses of vaccine formulation, which were able to induce a strong and potentially CD8+ T response.

Higher In Vivo Cytotoxicity of Specific CD8+ T After the Rapamycin Treatment

Another essential effector function involved in intracellular pathogens dissemination control is the direct cytotoxicity performed by NK and CD8+ T cells, releasing cytotoxic granules, such as perforins, granzymes B and granulysin, which are responsible for forming pores on the plasma membrane of target infected cells as well as inducing apoptosis. Thus, the cytotoxic activity of VNHRFTLV-specific CD8+ T-cells in C57BL/6 mice immunized with 10-fold lower doses of plasmid adenovirus and treated with rapamycin or vehicle was analyzed at 35 days after priming. The in vivo cytotoxicity assay was evaluated using adoptive transfer of labeled cells with two concentrations of CFSE dye, CFSEHigh and CFSELow. Only the CFSEHigh population was pulsed with 2.5 mM of the VNHRFTLV ASP2 peptide. Both populations were transferred to recipient mice of the experimental groups (Gr.1L, Gr.2L and Gr.3L) and, after 15 hours, we analyzed the percentage of lysis in CFSEHigh cells. The cytotoxic activity of VNHRFTLV-specific CD8+ T-cells was similar in both immunized groups, e.g., 97.6% in Gr.2L and 95.07% in Gr.3L (Supplementary Figure 5), which corroborates with our previous findings showing a strong cytotoxic activity.

FIGURE 3 | Rapamycin increased the frequency of specific CD8+ T cells and IFNγ production from mice immunized with reduced doses, after 35 or 95 days from priming. C57BL/6 mice were immunized i.m. with plasmid (10 µg) and adenovirus (2 x 10⁷ pfu) according to the experimental groups described in the method section. They were also treated daily with rapamycin or vehicle (i.p.) for 34 days. On days 35 or 95 after priming, splenic cells were collected for surface staining of anti-CD8 and H2Kb-VNHRFTLV pentamer or cultured with the specific peptide VNHRFTLV for ELISpot or CBA assay. (A) FACS charts show the frequency of CD8+ and H2Kb-VNHRFTLV+ cells in the spleen. The dot-plots correspond to the representative mice (median) of the group. Numbers represent the frequencies of CD8+ H2Kb-VNHRFTLV+ cells in the spleen. (B, D) The total number of specific CD8+ T cells was estimated. (C, E) Number of IFNγ producing cells by ELISpot. SFC: Spot-forming cells. (F) The supernatant of splenocytes from mice immunized for 95 days cultured for 48 hours was used to measure the indicated cytokines by flow cytometry. Statistical analysis was performed using the One-Way ANOVA and Tukey’s HSD tests. Asterisks indicate significant differences among groups, defined as *P < 0.05, **P < 0.01, and ***P < 0.001. Data referring to 4 mice per group and representing 4 independent experiments. N.S, Non-significant.
induced by heterologous prime-boost immunization using the ASP2 (De Alencar et al., 2009).

Therefore, we performed another cytotoxicity assay lowering the concentrations of VNHRFTLV peptide, trying to reveal any beneficial effect of rapamycin treatment on cytotoxic activity. For that, two dyes were used to sort 3 different populations: CFSE\textsuperscript{Low}, CFSE\textsuperscript{High} and PKH\textsuperscript{+}. Both CFSE\textsuperscript{High} and PKH\textsuperscript{+} populations were pulsed with the peptide at a final concentration of 500 nM and 50 nM, respectively (Figure 4). After 15 hours, rapamycin-treated mice (Gr.3L) exhibited a higher percentage of cytotoxic activity against VNHRFTLV\textsuperscript{+} target cells of CFSE\textsuperscript{High} (500 nM peptide) and PKH\textsuperscript{+} (50 nM peptide) populations compared with the cytotoxic activity observed in vector control Gr.1L and vehicle-injected Gr.2L mice (Figures 4A, B). Similar results were found at 95 days after priming. As expected, the main difference between the two immunized groups was the cytotoxic activity of CD8\textsuperscript{+} T-cells on the PKH\textsuperscript{+} target cell population, pulsed with the lowest concentration (50 nM) of the specific VNHRFTLV peptide (Figure 4B).

**Treatment With Rapamycin Increased the Survival of the Highly Susceptible A/Sn Mice Immunized With Low Doses After Challenge**

Once the putative protective profiles of CD8\textsuperscript{+} T-cells induced by vaccination have been improved when combined with rapamycin treatment, we challenged highly susceptible A/Sn mice with *T. cruzi* and survival was registered. Since heterologous prime-boost immunization can induce a protective response, mice groups were immunized with 10-fold lower doses of plasmid/adenovirus and treated with rapamycin or vehicle. Thirty-five days after priming, mice were challenged with 150 trypomastigotes forms of the Y strain of *T. cruzi*. The parasitemia and survival ratio were monitored daily.

Parasitemia (Figure 5A) was followed from day 5 post infection, and no significant difference were detected between Gr.2L and Gr.3L. Surprisingly, as shown in the survival curve (Figure 5B), 42.8% of mice from Gr.2L survived, while the rapamycin-treated mice (Gr.3L) showed 100% of survival rate (Log-rank p = 0.0218). In an independent experiment, rapamycin alone was not able to protect A/Sn mice from the experimental challenge (Supplementary Figure 6). These results demonstrate the adjuvant effect of rapamycin when combined with the vaccination, even with 10-fold lower concentrations of plasmid/adenovirus, inducing a protective immune response generated by prime-boost ASP2 immunization.

**Rapamycin Improved the Protective Immune Response Generated by Heterologous Prime-Boost Protocol in A/Sn Mice**

To verify whether the CD8\textsuperscript{+} T-cell response in A/Sn mice was also favored by the immunization combined with the rapamycin treatment, we challenged highly susceptible A/Sn mice with *T. cruzi* and survival was registered. Since heterologous prime-boost immunization can induce a protective response, mice groups were immunized with 10-fold lower doses of plasmid/adenovirus and treated with rapamycin or vehicle. Thirty-five days after priming, mice were challenged with 150 trypomastigotes forms of the Y strain of *T. cruzi*. The parasitemia and survival ratio were monitored daily.

Parasitemia (Figure 5A) was followed from day 5 post infection, and no significant difference were detected between Gr.2L and Gr.3L. Surprisingly, as shown in the survival curve (Figure 5B), 42.8% of mice from Gr.2L survived, while the rapamycin-treated mice (Gr.3L) showed 100% of survival rate (Log-rank p = 0.0218). In an independent experiment, rapamycin alone was not able to protect A/Sn mice from the experimental challenge (Supplementary Figure 6). These results demonstrate the adjuvant effect of rapamycin when combined with the vaccination, even with 10-fold lower concentrations of plasmid/adenovirus, inducing a protective immune response generated by prime-boost ASP2 immunization.
treatment, we performed the ex vivo assays. Splenocytes from A/Sn mice, immunized with 10-fold lower doses and treated with rapamycin or vehicle, were collected on days 35 or 95 after priming to measure the number of specific CD8\(^+\) T cells labeled with the multimer H2K\(^+\) restricted TEWETGQI peptide. In addition, we performed the intracellular staining to label CD107a, IFN\(\gamma\) and TNF, and ELISpot to measure the number of TEWETGQI-specific IFN\(\gamma\) producing CD8\(^+\) T-cells.

Initially, to quantify TEWETGQI-specific CD8\(^+\) T-cells, pools of splenocytes and lymph node cells from 4 mice per group were prepared. After labeling the cells with the multimer and anti-CD8, our data show that the frequency and absolute number of TEWETGQI-specific CD8\(^+\) T-cells increased in the rapamycin-treated mice (Gr.3L) (Figures 6A, B). Further, 35 after priming both ASP2-immunized groups (Gr.2L and Gr.3L) presented a population of TEWETGQI-specific CD8\(^+\) T-cells with an activated phenotype, characterized by expression of the cell markers CD44\(^{High}\), CD62L\(^{Low}\), KLRG1\(^{High}\) and CD127\(^{Low}\) (Figure 6C). At 95 days after priming, the TEWETGQI-specific CD8\(^+\) T-cells presented a reduced expression of CD127 and KLRG-1 (Figure 6C).

At 35 days and 95 days after priming, the frequencies of polyfunctional CD8\(^+\) T cells (CD107a\(^{+}\), IFN\(\gamma\)\(^{+}\) and TNF) (Figures 6D–E, G–H), and the absolute number of IFN\(\gamma\)\(^{+}\) CD8\(^+\) T cells, as revealed by ELISpot assay (Figures 6F, I), were significantly higher in splenocytes obtained from Gr.3L mice, compared to Gr.1L and Gr.2L, after ex vivo stimulation with the specific peptide. Altogether, these findings corroborate the improvement of vaccination after rapamycin treatment and explain the protective profile found after the challenge with the virulent T. cruzi Y strain, as described above.

Treatment With Rapamycin Increased In Vivo CD8\(^+\) T-Cell Proliferation
Since the number of ASP2-specific CD8\(^+\) T-cells increased in the rapamycin-treated mice (Gr.3 and Gr.3L), we hypothesized that CD8\(^+\) T-cells might show a differential proliferative response and clonal expansion after activation. Hence, the proliferation of CD8\(^+\) T-cells was analyzed in vivo using the BrdU incorporation approach. For that, A/Sn mice were immunized and treated with rapamycin or vehicle. After boosting, mice were treated every 48 hours with BrdU (2 mg/dose) until day 35 after priming.

According to Figure 7, ASP2-specific CD8\(^+\) T-cells from rapamycin-treated mice (Gr.3L) showed a higher incorporation of BrdU compared to Gr.1L and Gr.2L, due to the number of precursors activated by the boost. Therefore, during the expansion phase induced by vaccination, rapamycin treatment potentiates the proliferative response of ASP2-specific CD8\(^+\) T-cells.

Dendritic Cells Activated in the Presence of Rapamycin Lack Improvement in the Antigen Presentation Capacity of ASP2-Specific CD8\(^+\) T-Cells
Dendritic cells are specialized in antigen processing and presentation, capable of inducing the initial activation of T lymphocytes. The study performed by Amiel et al. (2012) showed that inhibition of mTOR during activation of dendritic cells derived from bone marrow (BMDC) prolonged their useful life and increased the expression of costimulatory molecules, essential for the antigen presentation. In addition, a tuberculosis vaccine (BCG) study that employed the stimulation of dendritic cells in the presence of rapamycin led to an increase in T cell activation (Jagannath et al., 2009). Hence, analyzing the role of dendritic cells antigen presentation for CD8\(^+\) T-cells during immunization appeared to be important. For that purpose, BMDC of C57Bl/6 mice were generated in vitro for 7 days, incubated with the ASP2-carrying adenovirus vector (MOI = 50) or the VNHRFTLV peptide (10 \(\mu\)g/ml) in the presence of absence of rapamycin (1 \(\mu\)M). In some conditions, BMDC were primed/matured with LPS (200 ng/ml) for 3 hours. As shown in Figures 8A, B, the expression level of costimulatory molecules (CD86 and CD40) and MHC class I (H2K\(^{B}\)) in CD11c\(^+\) cells were analyzed. We observed that expression levels of these markers were similar in dendritic cells stimulated in the presence or absence of rapamycin.

Next, we evaluated the antigen presentation capacity of BMDC stimulated in the presence of rapamycin to activate ASP2-specific CD8\(^+\) T-cells. Purified CD8\(^+\) cells from mice previously immunized with AdASP-2 were co-cultured with antigen-loaded BMDC under the same conditions as described above.
above, for 24 hours. The frequency of IFNγ-producing cells was detected by ELISpot. Interestingly, unlike expected, the in vitro antigenic presentation by BMDC in the presence of rapamycin decreased CD8⁺ T-cell activation, since the number of IFNγ-secreting cells was lower with the VNHRFTLV peptide or AdASP-2 and rapamycin (Figure 8C).

**DISCUSSION**

The heterologous prime-boost strategy is a well-established protocol capable of generating an effective response by inducing specific CD8⁺ T-cells against *T. cruzi*. The characterization of the phenotype and function of specific CD8⁺ T-lymphocytes show that these cells secrete IFNγ and TNF, express CD107a and are highly cytotoxic in vivo (De Alencar et al., 2009). Furthermore, this protocol was able to protect highly susceptible mice in experimental challenges with *T. cruzi* (De Alencar et al., 2009; Dominguez et al., 2011; Rigato et al., 2011). However, we showed here that treatment with rapamycin during immunization was able to potentiate the response of -specific CD8⁺ T-cells.

The number and frequency of immunization-specific CD8⁺ T-cells increased significantly in the rapamycin-treated mice,
even after 95 days after priming. It implies that cell contraction was delayed, and rapamycin treatment elicited memory precursor CD8+ T-cells rather than short-lived cells. In addition, specific CD8+ T-cells generated by immunization and rapamycin treatment showed a TK phenotype after 35 days from priming, and acquire subsequently a TEM profile, which was previously characterized in studies by our group (Rigato et al., 2011). Although rapamycin treatment has been reported to modulate the transition from effector to memory cells, especially to TCM after viral infections and tumors (Araki et al., 2009; Li et al., 2011; Turner et al., 2011; Li et al., 2012; Mattson et al., 2014; Shrestha et al., 2014), this modulation was not detected in our model. However, similar to our results, rapamycin combined with OX-40 stimulation induced a CD8+ memory population with a TEM profile following immunization with AdHu5 against LCMV (33), as well as found during the treatment with rapamycin in a carcinoma model (Jung et al., 2018).

The superiority between the TEM and TCM memory profiles is not yet fully established. Although TCM cells have been reported to provide superior long-term protection against systemic infections (Zaph et al., 2004; Klebanoff et al., 2005; Angelosanto and Wherry, 2010), this memory phenotype does not necessarily represent higher quality (Lanzavecchia and Sallusto, 2005). Indeed, CD8+ TEM cells generated by heterologous prime-boost immunization protocol confer immunity and protection against T. cruzi in acute and chronic infections (De Alencar et al., 2009; Haolla et al., 2009; Rigato et al., 2011; Araujo et al., 2014). TEM CD8+ T cells can respond fast during recall and this quality is crucial for protection of individuals in endemic areas.

Additionally, the analysis of the functional response performed by specific CD8+ T-cells showed that rapamycin-treated mice had an increased CD8+ T response, with greater magnitude and number of polyfunctional cells (IFNγ+, TNFα, CD107a+), especially 95 days after priming. Similar results in CD8+ T cell polyfunctionality improvement was found after rapamycin-treatment of rhesus macaques immunized against vaccinia, up to 140 days after immunization, as well as following infection with LCMV (Turner et al., 2011). These results were found here also in mice immunized with 10-fold lower doses of plasmid/adenovirus lasting up to 95 days after priming. Regarding the cytotoxic function, in vivo challenge, CD8+ T-cells cytotoxic activity was higher in the rapamycin-treated mice with both peptides concentrations, which enriches the adjuvant potential of rapamycin treatment during the immune challenge of CD8+ T-cells, generating functional cells and memory precursors (Araki et al., 2009; Pearce et al., 2009; Mannick et al., 2014; de Souza et al., 2016).

We described for the first time the treatment with rapamycin was able to improve the protection of susceptible A/Sn mice immunized with 10-fold lower doses of plasmid/adenovirus in the experimental challenge with T. cruzi. Surprisingly, the rapamycin-treated mice resisted the experimental challenge and showed maximum survival, while only 42.8% of the vehicle-injected mice (Gr.2L) resisted. Immune response assays performed in A/Sn mice also showed that specific CD8+ T-cell frequency was higher in the rapamycin-treated group in the spleen and lymph node, as well as the production of IFNγ and the number of polyfunctional cells. Taken together, these results strongly confirm the positive effect of rapamycin during immunization, as differences were found in distinct mouse strains up to 95 days after the priming.

Related to the increase in specific CD8+ T population, the results obtained here suggest that rapamycin induced a higher proliferation rate of specific CD8+ T-cells during differentiation and expansion phase, which occurs concurrently with in vivo rapamycin treatment. Although it was reported by Araki (Araki et al., 2009) that after 30 days of viral challenge and rapamycin treatment there was minimal incorporation of BrdU into DNA of specific CD8+ T-cells in all groups, showing that the decrease in T-cell contraction was not due to increase of cell proliferation but probably by survival, our data indicate that modulation exerted by rapamycin may inhibit cell contraction by different mechanisms, depending on the infection model and vaccine protocol used.
By investigating the effect of rapamycin on dendritic cells and how it would influence cellular response, the treatment suppressed CD8+ T-cell presentation and activation ability. This result corroborates previous studies showing that inhibition of mTOR appears to suppress DCs differentiation and maturation, so the cells exposed to rapamycin have an impaired ability to stimulate T-cells and cytokine production (Hackstein et al., 2003; Araki et al., 2010). Another in vitro study showed a suppressive effect on some aspects of DCs function at high doses of rapamycin, while at decreasing doses this effect was reversed, promoting the inflammatory function of cytokines (Gammon et al., 2017). Taken together, these data suggest that mTOR signaling has several effects on both inhibitory and stimulatory dendritic cells.

It is important to mention that our results presented some limitations, including the small sample size used in both in vivo and in vitro experiments as well as the use of splenocyte’s pools instead of individual splenocytes in the multimer experiments with A/Sn mice. Despite that, our findings are exciting and open new approaches to understand and validate the modulation made by rapamycin in vaccine context.

By knowing this, it is not clear how the blockage by rapamycin and mTOR pathways may interact synergistically to improve CD8+ T-cell memory. Several published studies have demonstrated that autophagy and metabolic switches are important for memory development (Araki et al., 2009; Pearce et al., 2009; Jagannath and Bakhru, 2012; Puleston et al., 2014; Xu et al., 2014; Chang and Pearce, 2016). Following activation, CD8+ T-cell memory arising from priming the differentiation pathway of DCs is preserved for a long period. By investigating the effect of rapamycin on dendritic cells and how it would influence cellular response, the treatment suppressed CD8+ T-cell presentation and activation ability. This result corroborates previous studies showing that inhibition of mTOR appears to suppress DCs differentiation and maturation, so the cells exposed to rapamycin have an impaired ability to stimulate T-cells and cytokine production (Hackstein et al., 2003; Araki et al., 2010). Another in vitro study showed a suppressive effect on some aspects of DCs function at high doses of rapamycin, while at decreasing doses this effect was reversed, promoting the inflammatory function of cytokines (Gammon et al., 2017). Taken together, these data suggest that mTOR signaling has several effects on both inhibitory and stimulatory dendritic cells.

It is important to mention that our results presented some limitations, including the small sample size used in both in vivo and in vitro experiments as well as the use of splenocyte’s pools instead of individual splenocytes in the multimer experiments with A/Sn mice. Despite that, our findings are exciting and open new approaches to understand and validate the modulation made by rapamycin in vaccine context.

By knowing this, it is not clear how the blockage by rapamycin and mTOR pathways may interact synergistically to improve CD8+ T-cell memory. Several published studies have demonstrated that autophagy and metabolic switches are important for memory development (Araki et al., 2009; Pearce et al., 2009; Jagannath and Bakhru, 2012; Puleston et al., 2014; Xu et al., 2014; Chang and Pearce, 2016). Following activation, CD8+ T-cell memory arising from priming the differentiation pathway of DCs is preserved for a long period. By investigating the effect of rapamycin on dendritic cells and how it would influence cellular response, the treatment suppressed CD8+ T-cell presentation and activation ability. This result corroborates previous studies showing that inhibition of mTOR appears to suppress DCs differentiation and maturation, so the cells exposed to rapamycin have an impaired ability to stimulate T-cells and cytokine production (Hackstein et al., 2003; Araki et al., 2010). Another in vitro study showed a suppressive effect on some aspects of DCs function at high doses of rapamycin, while at decreasing doses this effect was reversed, promoting the inflammatory function of cytokines (Gammon et al., 2017). Taken together, these data suggest that mTOR signaling has several effects on both inhibitory and stimulatory dendritic cells.
T-cells increase their glucose uptake and produce ATP by glycolysis through mTORC1 signaling. After the contraction phase, the memory population acquires a catabolic metabolism based on oxidative phosphorylation by the oxidation of fatty acids (FAO) and amino acids (Jones and Thompson, 2007). Pearce (Pearce et al., 2009) demonstrated that fat acid oxidation regulates memory development of CD8\(^+\) T-cells. Additionally, autophagy has been also described as important to memory formation of CD8\(^+\) T-cells due to the molecules recycling, damage repairing and product substrates for oxidative phosphorylation and FAO (Puleston et al., 2014; Xu et al., 2014). Since activation and other cellular processes lead to activation of mTOR, which induces glycolysis to support cell growth, proliferation and cell function (Chang and Pearce, 2016), it will be necessary to examine whether mTOR inhibition during immunization could interfere with T cell metabolism and bioenergetic capacity, polarizing the response to a metabolic profile similar to long-term memory cells.

The induction of memory cells is important due to long-lasting persistence, but also due to the ability to respond in the antigen recall. A catabolic capacity and greater mitochondrial mass confer the ability to respond fast and powerfully against the antigen, providing long-lasting protection (van der Windt et al., 2013). Therefore, the interest in generating a functional memory population through modulating their metabolic profile and energy capacity, will have more concern in the vaccine development field against chronic diseases and tumors.

Although rapamycin inhibition of mTOR has been reported to impair the differentiation of effector CD8\(^+\) T-cells, lead to loss of function, failure to control viral infections and cellular energy (Araki et al., 2018; Yao et al., 2013; Goldberg et al., 2014), this was not observed in this study. Indeed, it was evident that treatment with rapamycin in our vaccination model does not impair the differentiation of the specific CD8\(^+\) T population, cytokine production and cytotoxic activity, both in the effector and memory phases, which culminates in increased protection after challenge with \(T. cruzi\).

Importantly, the dose of rapamycin used in our study and others cited was suboptimal, since low doses were used compared to treatments aimed an immunosuppression effect (Araki et al., 2009; Araki et al., 2010; Gammon et al., 2017). In vivo drug’s administration was unable to completely block mTOR signaling and this inhibition occurs in a dose-dependent manner (Araki et al., 2009; Gammon et al., 2017), as observed in CD8\(^+\) T-cells when mTOR expression was decreased by RNAi, suggesting that rapamycin stimulates the formation of memory CD8\(^+\) T-cells by incompletely inhibition of mTOR signaling. Higher doses of rapamycin may result in suppression of CD8\(^+\) T cell expansion (Araki et al., 2009).

Given that mTOR signaling plays a central role in regulating cellular responses, this appears to be a potential pathway to be explored for modulating immune responses induced by vaccines (Sallusto et al., 2010). Here, we have shown for the first time the use of rapamycin improves functional qualities as well as the frequency of specific CD8\(^+\) T-cells generated by heterologous prime-boost immunization against \(T. cruzi\). This adjuvant effect was seen during the effector and memory phase, even with low immunogenic doses induced by the vaccination, besides promoting protection after experimental challenge. We speculate that mTOR inhibition by rapamycin is acting synergistically on CD8\(^+\) T-cells, modulating their activation, proliferation, differentiation and possibly their metabolism. Although some mechanisms need to be further elucidated, these findings suggest that strategic rapamycin treatment may improve effector and memory cell development in response to vaccine protocols, offering a new method for adjusting the desired immune response as well as plasticity, phenotype and cellular function.

In order to induce a population with a phenotype that provides optimal protection and functional qualities of memory CD8\(^+\) T-cells against the target pathogen, we provided herein a novel approach to upgrade the efficacy of genetic vaccines against intracellular infections, such as Chagas disease.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Ethical Committee for Animal Experimentation at the Federal University of Sao Paulo, registered under number 9959021014.

**AUTHOR CONTRIBUTIONS**

BM, MR and JV conceived and designed the experiments. BM, IN, CF, LC, CM, PD, and TV performed the experiments. BM, IN, CF, LC, CM, PD, and TV analyzed the experiment data. RG, JL-V, KB, GP and JV contributed with reagents and materials, and additional experiments design. BM wrote the manuscript. BM, JL-V, KB and JV reviewed the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (http://www.fapesp.br/) (BM: 2014/19422-5, 2016/02840-4; CF: 2015/08814-2; JV: 2012/22514-3, 2018/15607-1), Instituto Nacional de Ciência e Tecnologia em Vacinas (http://INCT.cnpq.br/), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (http://www.capes.gov.br/) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (http://cnpq.br/).
ACKNOWLEDGMENTS
This work is a tribute to the memory of Dr. Mauricio Martins Rodrigues.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2021.676183/full#supplementary-material

Supplementary Figure 1 | Expression of Ribosomal Phospho-S6 (PS6) protein in CD8+ T cells after treatment with rapamycin. Splenocytes from naïve mice were incubated with Concanavalin A (2 mg/mL) or rapamycin (100 nM) for one hour. Then, cells were stained with anti-CD8, fixed and permeabilized to anti-pS6K staining. (A) Dot-plots show the frequency of pS6K in singlets in each condition. (B) Histograms indicate the mean of fluorescence intensity of cells in medium (red line), treated with rapamycin (green line) or stimulated with ConA (blue line).

Supplementary Figure 2 | Strategy used for analysis of intracellular staining of cytokines in CD8+ T cells. Splenocytes were treated conform described in the methods section. (A) Gate strategy used for positive selection of CD8+ cells. (B) Dot-plots represent the frequencies of CD107a, IFNg and TNF in CD8+ T cells (B).

Supplementary Figure 3 | Immunophenotyping of specific CD8+ T cells from C57BL/6 mice immunized and treated with rapamycin or diluent after 35 days from priming. C57BL/6 mice were immunized via i.m. with plasmid (100 µg) and adenovirus (2 x 108 pfu) according to the experimental groups described in the method section. They were also treated daily with rapamycin or vehicle (i.p.), for 34 days. Splenocytes from naïve mice were stained with CFSE and CD8+ H2Kb-VNHRFTLV multimer and with the specific markers indicated above for flow cytometric analysis. Histograms show the expression of the markers in CD8+ H2Kb-VNHRFTLV* cells (blue and green lines) or CD8+ cells of naïve as control (red lines). Analyses were performed using cells pools of 4 mice and they are representative of two independent experiments. The numbers indicate the mean fluorescence intensity (MFI). The individual analysis of mice from each group presented similar results.

Supplementary Figure 4 | Immunophenotyping of specific CD8+ T cells of C57BL/6 mice immunized and treated with rapamycin or diluent after 95 from priming. C57BL/6 mice were immunized via i.m. with plasmid (100 µg) and adenovirus (2 x 108 pfu) according to the experimental groups described in the method section. They were also treated daily with rapamycin or vehicle (i.p.) for 34 days. After 35 days from priming, splenocytes were labeled with anti-CD8, H2Kb-VNHRFTLV* multimer and with the specific markers indicated above for flow cytometric analysis. Histograms show the expression of the markers in CD8+ H2Kb-VNHRFTLV* cells (blue and green lines) or CD8+ cells of naïve as control (red lines). Analyses were performed using cells pools of 4 mice and they are representative of two independent experiments. The numbers indicate the mean fluorescence intensity (MFI). The individual analysis of mice from each group presented similar results.

Supplementary Figure 5 | In vivo cytotoxicity of specific CD8+ T cells of C57BL/6 mice immunized and treated with rapamycin or diluent. C57BL/6 mice were immunized via i.m. with plasmid (100 µg) and adenovirus (2 x 108 pfu) according to the experimental groups described in the method section. They were also treated daily with rapamycin or vehicle (i.p.), for 34 days. Splenocytes from naïve mice were stained with CFSE in 2 different concentrations. CFSE−population was pulsed with peptide VNHRFTLV in an final concentration of 2 nM. CFSElow was the negative control. Stained cells were transferred to the experimental groups and, after 14 hours, spleens were harvested to quantify the frequency of stained cells. (A) Histograms represent the frequencies of CFSEhigh and CFSElow in each group. (B) Percentage of CD8+ T mediated cytotoxicity, with mean ± SD. Results from one experiment and 4 mice per group. Statistical analysis was performed using the One-Way ANOVA and Tukey’s HSD tests. Asterisks indicate significant differences among groups, defined as *P < 0.05, **P < 0.01, and ***P < 0.001. N.S., Non-significant.

Supplementary Figure 6 | Experimental challenge of A/sn mice after treatment with rapamycin or vehicle. A/sn mice were treated daily with rapamycin or vehicle (PBS) for 34 days. On the last day, mice were infected with 150 blood trypomastigotes of Y strain of T. cruzi. (A) Parasitemia was monitored daily between days 6 and 15 after challenge. The parasitemia values were low and consistent. (B) The survival rate was also followed and analyzed by Log-rank (Mantel-Cox) test (all groups p = 0.0285). Results from 4 mice per group.

REFERENCES
Moraschi et al. Rapamycin Improves CD8+ T-Cell Response


**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2021 Moraschi, Noronha, Ferreira, Cariste, Monteiro, Denapoli, Vrechi, Pereira, Gazzinelli, Lannes-Vieira, Rodrigues, Borotuci and Vasconcelos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**